A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors

ConclusionFenretinide emulsion intravenous infusion had a manageable safety profile and achieved higher plasma steady-state concentrations of the active metabolite compared to previous capsule formulations. Single-agent activity was minimal but combinatorial approaches are under evaluation.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research